Stifel lowered the firm’s price target on Orthofix (OFIX) to $18 from $22 and keeps a Buy rating on the shares. The firm updated models across its medical technology and supplies coverage following Q4 reporting from the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OFIX:
- Orthofix International Maps Steady Growth After Earnings
- Orthofix price target lowered to $20 from $24 at Canaccord
- Orthofix Medical: Strengthening Growth Momentum and Profitability Supports Compelling Buy-Rated Valuation
- Orthofix price target lowered to $17 from $18 at Barrington
- Orthofix reports Q4 EPS (6c) vs. (75c) last year